High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting

References

• Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386.
   PubMed Web of Science ®Google Scholar
• Maciejko L, Smalley M, Goldman A. Cancer immunotherapy and personalized medicine: emerging technologies and biomarker-based approaches. J Mol Biomark Diagn. 2017;8(5). doi:10.4172/2155-9929.1000350.
   PubMedGoogle Scholar
• Adashek JJ, Subbiah V, Kurzrock R. From tissue-agnostic to n-of-one therapies: (r)evolution of the precision paradigm. Trends Cancer. 2021;7(1):15–28. doi:10.1016/j.trecan.2020.08.009.
   PubMed Web of Science ®Google Scholar
• Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision n-of-one strategy. Nat Commun. 2020;11(1):4965. doi:10.1038/s41467-020-18613-3.
   PubMed Web of Science ®Google Scholar
• Sicklick JK, Kato S, Okamura R, Patel H, Nikanjam M, Fanta PT, Hahn ME, De P, Williams C, Guido J, et al. Molecular profiling of advanced malignancies guides first-line n-of-1 treatments in the i-predict treatment-naive study. Genome Med. 2021;13(1):155. doi:10.1186/s13073-021-00969-w.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi:10.1016/j.ccell.2020.10.001.
   PubMed Web of Science ®Google Scholar
• Debatisse M, Malfoy B. Gene amplification mechanisms. Adv Exp Med Biol. 2005; 570:343–361.
   PubMed Web of Science ®Google Scholar
• Smith KA, Agarwal ML, Chernov MV, Chernova OB, Deguchi Y, Ishizaka Y, Patterson TE, Poupon MF, Stark GR. Regulation and mechanisms of gene amplification. Philos Trans R Soc Lond B Biol Sci. 1995;347(1319):49–56.
   PubMed Web of Science ®Google Scholar
• Matsui A, Ihara T, Suda H, Mikami H, Semba K. Gene amplification: mechanisms and involvement in cancer. Biomol Concepts. 2013;4(6):567–582. doi:10.1515/bmc-2013-0026.
   PubMedGoogle Scholar
• Albertson DG. Gene amplification in cancer. Trends Genet. 2006;22(8):447–455. doi:10.1016/j.tig.2006.06.007.
   PubMed Web of Science ®Google Scholar
• Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, Ji HP, Maley CC. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22(1):105–113. doi:10.1038/nm.3984.
   PubMed Web of Science ®Google Scholar
• Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O, et al. Integrated analysis of tp53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28(11):3010. doi:10.1016/j.celrep.2019.08.061.
   PubMed Web of Science ®Google Scholar
• Li AM, Boichard A, Kurzrock R. Mutated tp53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. Cancer Biol Ther. 2020;21(1):95–100. doi:10.1080/15384047.2019.1665956.
   PubMed Web of Science ®Google Scholar
• Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342(6250):705–708. doi:10.1038/342705a0.
   PubMed Web of Science ®Google Scholar
• Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, et al. Tp53 alterations correlate with response to VEGF/vegfr inhibitors: implications for targeted therapeutics. Mol Cancer Ther. 2016;15(10):2475–2485. doi:10.1158/1535-7163.MCT-16-0196.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994;22(17):3551–3555.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, et al. 2021. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: an nrg oncology study. Gynecol Oncol. 161(1):113–121.
   PubMed Web of Science ®Google Scholar
• Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018;25(1):133–143. doi:10.1038/cdd.2017.174.
   PubMed Web of Science ®Google Scholar
• Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 2020;5(11). doi:10.1172/jci.insight.134824.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al. Driver mutations in tp53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56. doi:10.1002/path.2696.
   PubMed Web of Science ®Google Scholar
• Burtness B, Deneka A, Baca Y, Serebriiskii I, Parker MI, Nicolas E, Lee JW, Wise-Draper T, Sukari A, Somer BG, et al. Correlation of tumor mutational burden (tmb) with cdkn2a and tp53 mutation in HPV-negative head and neck squamous cell carcinoma (hnscc). J Clin Oncol. 2020;38(15_suppl):6552. doi:10.1200/JCO.2020.38.15_suppl.6552.
   Web of Science ®Google Scholar
• Boichard A, Lippman SM, Kurzrock R. Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden. J Hematol Oncol. 2021;14(1):201. doi:10.1186/s13045-021-01211-1.
   PubMed Web of Science ®Google Scholar
• Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. Gistic2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41. doi:10.1186/gb-2011-12-4-r41.
   PubMed Web of Science ®Google Scholar